BlackRock Amends 4D Molecular Therapeutics Stake to 7.0%
Ticker: FDMT · Form: SC 13G/A · Filed: Jan 25, 2024 · CIK: 1650648
| Field | Detail |
|---|---|
| Company | 4d Molecular Therapeutics, INC. (FDMT) |
| Form Type | SC 13G/A |
| Filed Date | Jan 25, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, stake-change
TL;DR
**BlackRock now owns 7.0% of 4D Molecular Therapeutics, signaling continued institutional interest.**
AI Summary
BlackRock Inc. filed an amended SC 13G/A on January 25, 2024, disclosing its ownership in 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT). As of December 31, 2023, BlackRock reported beneficial ownership of 3,740,789 shares of Common Stock, representing 7.0% of the company's outstanding shares. This is an amendment to their previous filing, indicating a change in their holdings, which matters to investors as BlackRock is a major institutional investor whose movements can signal confidence or concern in the stock.
Why It Matters
BlackRock's updated stake shows their current level of investment in 4D Molecular Therapeutics, which can influence market perception and potentially the stock price.
Risk Assessment
Risk Level: low — This filing indicates a major institutional investor's position, which generally adds stability and transparency to the stock.
Analyst Insight
Investors should note BlackRock's continued significant stake as a sign of institutional confidence, but also monitor future filings for any substantial changes in their position.
Key Numbers
- 3,740,789 — Shares Beneficially Owned (This is the total number of 4D Molecular Therapeutics shares BlackRock Inc. reported owning as of December 31, 2023.)
- 7.0% — Percentage of Class (This represents the portion of 4D Molecular Therapeutics' Common Stock that BlackRock Inc. beneficially owns, indicating a significant institutional holding.)
Key Players & Entities
- BlackRock Inc. (company) — the institutional investor filing the SC 13G/A
- 4D Molecular Therapeutics, Inc. (company) — the subject company in which BlackRock holds shares
- 3,740,789 (dollar_amount) — number of shares beneficially owned by BlackRock
- 7.0% (dollar_amount) — percentage of class beneficially owned by BlackRock
- December 31, 2023 (date) — date of the event requiring the filing
Forward-Looking Statements
- BlackRock will maintain a significant stake in 4D Molecular Therapeutics, indicating continued long-term interest. (BlackRock Inc.) — medium confidence, target: Q4 2024
FAQ
What is the purpose of this SC 13G/A filing by BlackRock Inc.?
This SC 13G/A filing is an amendment (Amendment No: 2) by BlackRock Inc. to update its beneficial ownership in 4D Molecular Therapeutics Inc., as required by Rule 13d-1(b) of the Securities Exchange Act of 1934.
As of what date did BlackRock Inc. report its beneficial ownership in 4D Molecular Therapeutics Inc.?
BlackRock Inc. reported its beneficial ownership in 4D Molecular Therapeutics Inc. as of December 31, 2023, which is stated as the 'Date of Event Which Requires Filing of this Statement'.
How many shares of 4D Molecular Therapeutics Inc. Common Stock does BlackRock Inc. beneficially own according to this filing?
According to the filing, BlackRock Inc. beneficially owns 3,740,789 shares of 4D Molecular Therapeutics Inc. Common Stock.
What percentage of 4D Molecular Therapeutics Inc.'s Common Stock does BlackRock Inc.'s ownership represent?
BlackRock Inc.'s beneficial ownership represents 7.0% of 4D Molecular Therapeutics Inc.'s Common Stock, as indicated in the filing.
Under which rule was this Schedule 13G filed?
This Schedule 13G was filed under Rule 13d-1(b), as indicated by the 'X' next to 'Rule 13d-1(b)' on the cover page.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 25, 2024 regarding 4D Molecular Therapeutics, Inc. (FDMT).